Prostate cancer is the second-leading cause of cancer death among men in the U.S., with more than 330,000 cases expected to be diagnosed in 2026, according to urologic cancer specialist Matthew R. Cooperberg, M.D.
UCTV has distributed more than 125 programs about prostate cancer for patients and their loved ones as part of UCSF’s annual Patient Conference on Prostate Cancer.
This popular series offers practical guidance on the basics of prostate cancer, treatment options, the latest research, and healthy lifestyle choices.
Prostate Cancer Overview: What’s New and Exciting?
Prostate cancer affects screening, treatment, and health equity in important ways. Dr. Matthew Cooperberg, UCSF, explains how better use of PSA testing and risk stratification shapes earlier detection while reducing overdiagnosis and overtreatment. Cooperberg examines screening policy, racial disparities, and active surveillance, helping clarify who needs testing, biopsy, or treatment. This work helps explain why individualized care matters and points toward more precise decisions that protect both survival and quality of life.
Eat Smart, Move More: 5 Takeaways for Prostate Cancer Health
UCSF researchers June Chan and Stacey Kenfield discuss at evidence-based strategies for improving prostate cancer outcomes through exercise and diet. They highlight studies showing that physical activity—including resistance and high-intensity interval training—is linked to lower risk of prostate cancer progression and death. They discuss plant-based diets, dietary indices, and specific foods like tomatoes, fish, and nuts, along with the benefits of substituting plant oils for butter. Their analysis includes findings on racial disparities and underscores the need for inclusive research. They also describe current clinical trials exploring lifestyle tools and offer guidance on navigating diet and exercise choices during cancer survivorship.
Treatment of Advanced Prostate Cancer
Experts from UCSF outline the latest treatments and research for advanced prostate cancer, highlighting improved outcomes and promising therapies. Dr. Kelly Fitzgerald reviews intensified androgen deprivation therapy (ADT) and the evolving role of imaging, triplet therapy, and local treatments. Dr. Ivan de Kouchkovsky shares how radioligand therapies like Lutetium-177 PSMA target cancer with precision and are now approved earlier in care. Dr. David Oh explains immunotherapy strategies, including cancer vaccines and checkpoint inhibitors, and explores new options like bispecific T-cell engagers. Dr. Terry Friedlander discusses bone health and the impact of hormone therapy, offering strategies to reduce fracture risk and improve quality of life.